Electromed, Inc.
Electromed develops, manufactures, markets and sells airway clearance products for patients with compromised pulmonary function. Its main product is the prescription-only SmartVest Airway Clearance System, which provides high frequency chest wall oscillation therapy. The system is available in SmartVest SQL and SmartVest Clearway models, with garments sized for children and adults. Electromed also markets single-patient-use SmartVest and SmartVest Wrap products to health care providers for hospital use. Electromed primarily sells directly to patients and providers in the U.S. homecare market. It receives patient referrals from clinicians, processes insurance claims, delivers and trains patients to use the system, and earns money through payer reimbursement and direct patient payments. It also sells to hospitals and uses independent distributors for international sales. Electromed is headquartered in New Prague, Minnesota, where it assembles and tests its products.
No SEC Form 4 filings for $ELMD in the last 30 days.
See all $ELMD insider activity →Electromed Inc. (ELMD) reported Q1 FY2027 revenue of $18.7M, missing expectations, but earnings of $0.32 per share beat forecasts. Gross margin improved to 80% from 78.1% YoY. The stock fell 2.69% in after-hours trading. The company highlighted its strong profitability and market opportunity in bronchiectasis treatment.
Electromed reported Q1 FY27 revenue of $18.682M, up 10.6% YoY, and net income of $2.761M, up 29.3%, driven by homecare growth. Buybacks were the main use of financing cash. The company's liquidity plans depend on renewing or replacing a credit facility due in December 2026.
Electromed, Inc. (ELMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Electromed, Inc. Delivers Continued Growth in Fiscal 2027 First Quarter 16th consecutive quarter of year-over-year revenue and operating income growth NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative a
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning ELMD (Electromed, Inc.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 1 bearish.
Recent ELMD coverage spans earnings, insider activity and financial news.
Revenue shortfall outweighs margin beat, prompting modest downside pressure.
Earnings beat on revenue and profit growth may lift the stock modestly.
Strong top‑line and margin expansion likely supports a price uptick.
Positive earnings surprise with double‑digit revenue growth and expanding margins.
Revenue growth and leadership transition may affect valuation and investor sentiment.
AlphAI scores every news story that mentions ELMD with an AI model for sentiment and relevance, and aggregates insider trades from Electromed, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Electromed Inc. (ELMD) reported Q1 FY2027 revenue of $18.7M, missing expectations, but earnings of $0.32 per share beat forecasts. Gross margin improved to 80% from 78.1% YoY. The stock fell 2.69% in after-hours trading. The company highlighted its strong profitability and market opportunity in bronchiectasis treatment.
Electromed reported Q1 FY27 revenue of $18.682M, up 10.6% YoY, and net income of $2.761M, up 29.3%, driven by homecare growth. Buybacks were the main use of financing cash. The company's liquidity plans depend on renewing or replacing a credit facility due in December 2026.
Electromed, Inc. (ELMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Electromed, Inc. Delivers Continued Growth in Fiscal 2027 First Quarter 16th consecutive quarter of year-over-year revenue and operating income growth NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative a
Electromed, Inc. reported Q1 FY 2027 revenue of $18.7M, up 10.6% YoY, and net income of $2.8M, up 29.3% YoY. Diluted EPS was $0.32, compared to $0.25 in the prior year. This marks the 16th consecutive quarter of year-over-year growth for the company, according to the company.
Electromed (ELMD) reported Q4 2026 revenue growth of 11.6% to $19.4M, with full-year revenue up 15.3% to $73.8M. Growth was driven by home care and distributor channels, while hospital revenue declined 29%. The company expanded its sales force and highlighted its SmartVest product's market potential. CEO Jim Armstrong announced his planned retirement in April 2027.
Electromed, Inc. reported 15% Q4 home care revenue growth and 29% hospital revenue decline, driven by sales and longer sales cycles. The company expects double-digit growth in 2027, with strategic investments in digital solutions and sales force expansion. CEO James Cunniff will retire in April 2027. The company aims to expand payer coverage and product lines.
Electromed, Inc. (ELMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results Strong homecare revenue growth and expanded operating leverage drive record operating income in Fiscal 2026 NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed
Cunniff James L. (CEO and President) sold 9,700 shares of Electromed, Inc. (ELMD) at an average of $36.50 ($36.25–$37.77, $0.35M total) across 3 trades on 2026-06-08.
Nagel Bradley M. (Chief Financial Officer) sold 11,801 shares of Electromed, Inc. (ELMD) at an average of $36.35 ($36.34–$37.11, $0.43M total) across 2 trades on 2026-06-04.
